Philips’ VeriSight Pro 3D ICE Redefines Minimally Invasive Heart Care in Europe

Industry Insights from Next Move Strategy Consulting

As structural heart disease cases rise across Europe, Philips’ launch of the VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter marks a groundbreaking advancement in minimally invasive cardiac care. This innovative technology delivers real-time 2D and 3D imaging from within the heart, enhancing procedural precision and expanding access to patient-friendly interventions.

A Leap Forward in Cardiac Imaging

Traditional imaging methods like transesophageal echocardiography (TEE) often require general anesthesia, increasing patient risk and hospital resource demands. Philips’ VeriSight Pro 3D ICE catheter overcomes these challenges with a miniaturized ultrasound probe—approximately 3 millimeters in diameter—embedded at the tip of a steerable catheter. Navigated through the femoral vein into the heart chambers, it provides high-resolution imaging without the need for invasive techniques or anesthesia.

“This technology allows us to visualize cardiac anatomy in real time from inside the heart,” said Prof. Dr. Jörg Hausleiter, Ludwig-Maximilians-Universität (LMU) Munich, Germany. “It streamlines workflows and makes complex procedures more accessible to patients.”

Key Capabilities at a Glance:

Real-Time 2D and 3D Imaging: High-quality visualization directly from within the heart chambers.
Minimally Invasive Design: Eliminates the need for general anesthesia, reducing recovery time and costs.
xPlane and iRotate Technologies: Enables simultaneous dual-plane imaging and digital view adjustments without repositioning.
Integrated Ecosystem: Seamlessly connects with Philips’ EPIQ ultrasound systems and Azurion platform for end-to-end procedural support.
Versatile Applications: Supports transcatheter valve repair, left atrial appendage closure, and electrophysiology interventions.

Enhancing Efficiency and Patient Outcomes

VeriSight Pro addresses the growing demand for transcatheter valve repair and closure procedures by offering a less invasive alternative to TEE. By reducing the need for general anesthesia and Post-Anesthesia Care Unit (PACU) time, it shortens hospital stays and lowers costs. The catheter’s ability to image from within the heart provides physicians with precise control over device placement and procedural outcomes, all from a single access point.

As the first ICE catheter to miniaturize TEE’s 3D imaging technology, VeriSight Pro sets a new standard for procedural guidance. Its integration with Philips’ broader structural heart ecosystem, including tools like EchoNavigator, empowers clinicians to perform complex interventions with greater confidence and efficiency.

Industry Impact and Clinical Showcase

The introduction of VeriSight Pro in Europe aligns with the rising prevalence of structural heart disease and the need for scalable, patient-centric solutions. By simplifying imaging workflows and reducing procedural complexity, the technology is poised to transform how hospitals manage interventional suites.

Philips will showcase VeriSight Pro at EuroPCR 2025 in Paris (May 20–23), with key activities including:

A physician-led symposium, “Advanced Imaging in Structural Heart Disease Interventions,” featuring case studies from U.S. and European clinicians.
Hands-on training with Mentice simulators, in collaboration with Edwards Lifesciences.
An invite-only VR-based training program for left atrial appendage occlusion and tricuspid valve transcatheter edge-to-edge repair (TV TEER).

Redefining Structural Heart Care

With VeriSight Pro, Philips reinforces its commitment to advancing image-guided therapies that prioritize precision, efficiency, and patient comfort. This launch represents a pivotal step toward making minimally invasive heart procedures more accessible, empowering clinicians and improving outcomes for patients across Europe.

Source: https://www.philips.com/a-w/about/news/

Prepared by: Next Move Strategy Consulting